2O9 Stock Overview
Develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Renalytix Plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.12 |
| 52 Week High | UK£1.63 |
| 52 Week Low | UK£0.11 |
| Beta | 2.19 |
| 11 Month Change | -38.14% |
| 3 Month Change | -68.25% |
| 1 Year Change | -90.84% |
| 33 Year Change | -99.07% |
| 5 Year Change | n/a |
| Change since IPO | -98.63% |
Recent News & Updates
Recent updates
Shareholder Returns
| 2O9 | DE Healthcare Services | DE Market | |
|---|---|---|---|
| 7D | -42.3% | -1.9% | 0.09% |
| 1Y | -90.8% | -24.8% | 3.1% |
Return vs Industry: 2O9 underperformed the German Healthcare Services industry which returned -24.8% over the past year.
Return vs Market: 2O9 underperformed the German Market which returned 3.1% over the past year.
Price Volatility
| 2O9 volatility | |
|---|---|
| 2O9 Average Weekly Movement | 12.4% |
| Healthcare Services Industry Average Movement | 4.0% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.7% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 2O9's share price has been volatile over the past 3 months.
Volatility Over Time: 2O9's weekly volatility has decreased from 34% to 12% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | 102 | James McCullough | renalytix.com |
Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from electronic health record systems to generate a unique patient risk score. Its products are used in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery.
Renalytix Plc Fundamentals Summary
| 2O9 fundamental statistics | |
|---|---|
| Market cap | €20.98m |
| Earnings (TTM) | -€35.01m |
| Revenue (TTM) | €2.07m |
10.1x
P/S Ratio-0.6x
P/E RatioIs 2O9 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2O9 income statement (TTM) | |
|---|---|
| Revenue | US$2.22m |
| Cost of Revenue | US$2.26m |
| Gross Profit | -US$35.00k |
| Other Expenses | US$37.45m |
| Earnings | -US$37.49m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.24 |
| Gross Margin | -1.58% |
| Net Profit Margin | -1,687.80% |
| Debt/Equity Ratio | -84.1% |
How did 2O9 perform over the long term?
See historical performance and comparison